产品简介:骨质疏松症 - 具有高潜力备受期待的新药候补

产品简介:骨质疏松症 - 具有高潜力备受期待的新药候补 是由出版商Datamonitor在2011年11月所出版的。 这份英文市场调查报告书包含Pages: 208 价格从美金11400起跳。

简介

本报告提供随著患者人数增加而展现出潜在高收益性的骨质疏松症治疗药物市场相关数据，已上市贩售的治疗药物及开发平台相关调查分析，将其结果，概述为以下内容。

概要

• 触媒
• 要旨

执行摘要

• 策略性范围界定及其焦点
• 主要结果
• 相关报告书

市场定义及概要

• 产品概要

市贩产品概要

• Fosamax/Fosamax Plus D (alendronate，Merck & Co.)
• Actonel/Actonel with Calcium(risedronic acid，Sanofi/Warner Chilcott)
• Bonviva/Boniva(ibandronic acid，Roche/GlaxoSmithKline)
• Aclasta/Reclast(zoledronic acid，Novartis)
• Foruteo(teriparatide，Eli Lilly)
• Prolia(denosumab，Amgen/GlaxoSmithKline/第一三共)
• Evista(raloxifene，Eli Lilly)
• Conbriza/Viviant (bazedoxifene，Pfizer/Almirall)
• Protelos(strontium ranelate，Servier)
• Edirol (eldecalcitol，中外制药/大正制药)
• 其他骨质疏松症治疗药物

开发中产品概要

• Odanacatib (MK0822; Merck & Co.)
• ZT-031 (hPTH1-31; Zelos Therapeutics)
• ZP-PTH (hPTH1-34; Zosano Pharma)
• BA058 (PTH peptide fragment; Radius)
• EX101 (alendronate; EffRx/Nycomed)
• Almerol (alendronate; Merrion)
• Aprela (bazedoxifene with conjugated estrogens; Pfizer)
• SMC021 (salmon calcitonin; Novartis)
• Capsitonin (BN-002; Bone Medical)
• NBS101 (strontium malonate; Osteologix)
• 其他开发中的骨质疏松症治疗药物

参考文献

附表

目录

Description

Introduction

Despite major brands losing market exclusivity increasing cost competition, the osteoporosis market remains attractive. Leading osteoporosis companies continue to promote their products and develop their franchises while drug developers strive to bring their agents to market in an attempt to meet unmet need and tap into this potentially profitable patient population

Features and benefits

• Understand Datamonitor's independent appraisal of marketed brands and key pipeline agents indicated for treating osteoporosis
• Illustrate how pipeline and marketed drugs compare to one another in terms of clinical and commercial attributes
• Understand how marketed brands are positioned in the osteoporosis treatment algorithm and how they are perceived by treating physicians
• Evaluate the latest drug launches and barriers to increasing market share
• Determine to what extent future therapies satisfy the main clinical unmet needs in osteoporosis treatment

Highlights

• Forteo (teriparatide; Eli Lilly) further increased its class leading position after its launch in Japan in summer 2010. The biggest opportunity in the market remains for new safe and efficacious anabolic therapies, indeed several PTH analogs continue their development, in an attempt to become the first second generation PTH to reach the market.
• n 2010, Prolia (denosumab) was launched in the US and EU. Initial sales were modest and Amgen and its European partner GlaxoSmithKline need to continue marketing their product aggressively as a convenient bone strengthening drug in order to increase market share.
• Odanacatib (Merck & Co) is the most promising product in the pipeline due to its favorable clinical profile and Merck's market experience. However, with launch is expected only in 2015, Merck will face the large challenge of penetrating the highly saturated and genericized antiresorptive market.

Your key questions answered

• What are the key differentiating features of approved therapies for osteoporosis and how are they used in the daily management of the disease?
• How did Prolia perform upon launch and what strategies are Amgen and GlaxoSmithKline implementing to drive market penetration
• How do key opinion leaders and prescribers perceive available treatments for osteoporosis?
• Do pipeline products address key clinical unmet needs?
• What are the comparative strengths and weaknesses of the key osteoporosis brands and pipeline candidates?

TOC

Executive Summary

• Update details: November 2011
• Strategic scoping and focus
• Datamonitor key findings
• Related reports

OVERVIEW

• Catalyst
• Summary

MARKET DEFINITION AND OVERVIEW

• Product overview

MARKETED PRODUCT PROFILES

• Fosamax/Fosamax Plus D (alendronate; Merck & Co.)
• Drug profile
• Development overview
• SWOT analysis
• Product positioning
• Physician perception of Fosamax
• Clinical and commercial attractiveness
• Actonel/Actonel with Calcium (risedronic acid; Sanofi/Warner Chilcott)
• Drug profile
• Development overview
• SWOT analysis
• Product positioning
• Physician perception of Actonel
• Clinical and commercial attractiveness
• Bonviva/Boniva (ibandronic acid; Roche/GlaxoSmithKline)
• Drug profile
• Development overview
• SWOT analysis
• Product positioning
• Physician perception of Bonviva
• Clinical and commercial attractiveness
• Aclasta/Reclast (zoledronic acid; Novartis)
• Drug profile
• Development overview
• SWOT analysis
• Product positioning
• Physician perception of Aclasta
• Clinical and commercial attractiveness
• Forteo (teriparatide; Eli Lilly)
• Drug profile
• Development overview
• SWOT analysis
• Product positioning
• Physician perception of Forteo
• Clinical and commercial attractiveness
• Prolia (denosumab; Amgen/GlaxoSmithKline/Daiichi Sankyo)
• Drug profile
• Development overview
• SWOT analysis
• Product positioning
• Clinical and commercial attractiveness
• Evista (raloxifene; Eli Lilly)
• Drug profile
• Development overview
• SWOT analysis
• Product positioning
• Physician perception of Evista
• Clinical and commercial attractiveness
• Conbriza/Viviant (bazedoxifene; Pfizer/Almirall)
• Drug profile
• Development overview
• SWOT analysis
• Product positioning
• Clinical and commercial attractiveness
• Protelos (strontium ranelate; Servier)
• Drug profile
• Development overview
• SWOT analysis
• Product positioning
• Physician perception of Protelos
• Clinical and commercial attractiveness
• Edirol (eldecalcitol; Chugai/Taisho)
• Drug profile
• Development overview
• SWOT analysis
• Product positioning
• Clinical and commercial attractiveness
• Other marketed drugs for osteoporosis
• Bonoteo/Recalbon (minodronic acid; Astellas/Ono Pharmaceutical)
• Preotact (full-length PTH 1-84; NPS/Nycomed)
• Miacalcic (calcitonin-salmon; Novartis)
• Fortical (calcitonin-salmon; UniGene)

PIPELINE PRODUCT PROFILES

• Odanacatib (MK0822; Merck & Co.)
• Drug profile
• Development overview
• SWOT analysis
• Satisfaction of unmet needs
• Clinical and commercial attractiveness
• ZT-031 (hPTH1-31; Zelos Therapeutics)
• Drug profile
• Development overview
• SWOT analysis
• Satisfaction of unmet needs
• Clinical and commercial attractiveness
• ZP-PTH (hPTH1-34; Zosano Pharma/ Asahi Kasei)
• Drug profile
• Development overview
• SWOT analysis
• Satisfaction of unmet needs
• Clinical and commercial attractiveness
• BA058 (PTH peptide fragment; Radius)
• Drug profile
• Development overview
• SWOT analysis
• Satisfaction of unmet needs
• Clinical and commercial attractiveness
• EX101 (alendronate; EffRx/Nycomed)
• Drug profile
• SWOT analysis
• Satisfaction of unmet needs
• Clinical and commercial attractiveness
• Aprela (bazedoxifene with conjugated estrogens; Pfizer)
• Drug profile
• Development overview
• SWOT analysis
• Satisfaction of unmet needs
• Clinical and commercial attractiveness
• SMC021 (oral salmon calcitonin; Novartis)
• Drug profile
• Development overview
• SWOT analysis
• Satisfaction of unmet needs
• Clinical and commercial attractiveness
• Ostora (oral salmon calcitonin; Tarsa)
• Drug pro

相关商品

骨头疾病治疗相关市场调查报告书

全球及中国的骨质疏松症治疗药物市场:市场规模·市场趋势·市场预测(2010-2015年)
Osteoporosis Drug Market- Global And China Market Analysis, Size, Trends And Forecast (2010-2015)
价格 : US $ 2395
出版日期 : 2012年01月

中国的骨质疏松症市场分析与预测(2007年～2015年)
China Osteoporosis Market Analysis and Forecast, 2007 - 2015
价格 : US $ 1500
出版日期 : 2012年01月

全球肌肉骨骼疾病治疗药物的市场(到2017年为止)
Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014
价格 : US $ 3500
出版日期 : 2012年01月

Datamonitor发行的制药相关市场调查报告书

美国及EU主要5个国家的HIV药市场:市场预测

HIV Market Forecast

价格 : US $ 11400

出版日期 : 2012年02月

市场及产品预测:HIV - 患病人口的扩大与新STR剧增的欧美销售

Market and Product Forecasts: HIV - Rising prevalence and novel STRs boost sales in the US and Europe

价格 : US $ 11400

出版日期 : 2012年02月

FDA的Bydureon的认证:医生的见解

Bydureon FDA Approval: Physician Opinion

价格 : US $ 3800

出版日期 : 2012年02月

Email Alert(Email 通知) - 最新市场调查报告书

GII 将每天定期更新最新市场调查报书信息，选择您有兴趣的市场分类，我们将用Email的方式让您收到最新讯息!